SI1496912T1 - Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo - Google Patents

Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo

Info

Publication number
SI1496912T1
SI1496912T1 SI200332241T SI200332241T SI1496912T1 SI 1496912 T1 SI1496912 T1 SI 1496912T1 SI 200332241 T SI200332241 T SI 200332241T SI 200332241 T SI200332241 T SI 200332241T SI 1496912 T1 SI1496912 T1 SI 1496912T1
Authority
SI
Slovenia
Prior art keywords
brimonidine
timolol
combination
topical ophthalmic
ophthalmic use
Prior art date
Application number
SI200332241T
Other languages
English (en)
Slovenian (sl)
Inventor
Chin-Ming Chang
Gary J. Beck
Cynthia C. Pratt
Amy L. Batoosingh
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1496912(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of SI1496912T1 publication Critical patent/SI1496912T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/001—Arrangement of electric circuit elements in or on lighting devices the elements being electrical wires or cables
    • F21V23/002—Arrangements of cables or conductors inside a lighting device, e.g. means for guiding along parts of the housing or in a pivoting arm
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/003—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array
    • F21V23/004—Arrangement of electric circuit elements in or on lighting devices the elements being electronics drivers or controllers for operating the light source, e.g. for a LED array arranged on a substrate, e.g. a printed circuit board
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
    • F21V23/00—Arrangement of electric circuit elements in or on lighting devices
    • F21V23/02—Arrangement of electric circuit elements in or on lighting devices the elements being transformers, impedances or power supply units, e.g. a transformer with a rectifier
    • F21V23/023—Power supplies in a casing
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0066—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form characterised by the light source being coupled to the light guide
    • G02B6/0073—Light emitting diode [LED]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Power Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
SI200332241T 2002-04-19 2003-04-09 Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo SI1496912T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/126,790 US7030149B2 (en) 2002-04-19 2002-04-19 Combination of brimonidine timolol for topical ophthalmic use
EP03726234.2A EP1496912B9 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use
PCT/US2003/010885 WO2003088973A1 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use

Publications (1)

Publication Number Publication Date
SI1496912T1 true SI1496912T1 (sl) 2013-03-29

Family

ID=29215107

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332241T SI1496912T1 (sl) 2002-04-19 2003-04-09 Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo

Country Status (17)

Country Link
US (16) US7030149B2 (enExample)
EP (2) EP2241319A1 (enExample)
JP (1) JP2005523316A (enExample)
KR (1) KR100723189B1 (enExample)
CN (2) CN101664414A (enExample)
BR (1) BR0302584A (enExample)
CA (1) CA2440764C (enExample)
CY (1) CY1114048T1 (enExample)
DK (1) DK1496912T3 (enExample)
ES (1) ES2399045T3 (enExample)
MX (2) MXPA03008401A (enExample)
NO (1) NO326579B1 (enExample)
NZ (1) NZ528945A (enExample)
PT (1) PT1496912E (enExample)
SI (1) SI1496912T1 (enExample)
TW (1) TWI351959B (enExample)
WO (1) WO2003088973A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US20080051406A1 (en) * 2006-08-25 2008-02-28 Richard Graham Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100028266A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
JP5218167B2 (ja) 2009-03-11 2013-06-26 日立電線株式会社 コネクタ
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8317973B2 (en) * 2009-11-11 2012-11-27 Kemira Chemical, Inc. Polyester surfactants for deinking
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
BR112012017319A2 (pt) * 2009-12-22 2016-04-19 Allergan Inc composições e métodos para abaixar a pressão intraocular
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
PT2598119T (pt) 2010-07-29 2018-12-17 Allergan Inc Soluções de brimonidina e timolol isentas de conservantes
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN104114154A (zh) * 2011-12-16 2014-10-22 阿勒根公司 包含聚乙烯基己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)的眼用组合物
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
US20180078500A1 (en) * 2015-03-19 2018-03-22 Allergan, Inc. Fixed dose combination of brimonidine and timolol
CA3033507A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
MX2019014748A (es) * 2017-06-08 2020-08-03 Eye Therapies Llc Combinaciones de brimonidina de dosis baja y usos de las mismas.
US20200108064A1 (en) * 2017-06-08 2020-04-09 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
CN111132640B (zh) * 2017-09-25 2023-01-10 佛罗里达大学研究基金会股份有限公司 从含亲水药物的滴眼剂中除去防腐剂
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
AU2019246035B2 (en) * 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
US11871308B2 (en) * 2019-07-29 2024-01-09 TapText llc System and method for link-initiated dynamic-mode communications
US20220411482A1 (en) 2019-11-15 2022-12-29 Silk Technologies, Ltd. Stable formulations of silk-derived protein
IL293976A (en) 2019-12-19 2022-08-01 Tearclear Corp Preservative removal from eye drops
CN120617269A (zh) * 2025-06-16 2025-09-12 鲁南贝特制药有限公司 一种溴莫尼定噻吗洛尔滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4195085A (en) * 1975-09-26 1980-03-25 Merck & Co., Inc. Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
DE4201079C3 (de) 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
DE69425334T2 (de) 1993-12-17 2001-02-08 The Procter & Gamble Company, Cincinnati 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5564596A (en) 1994-05-05 1996-10-15 Allergan, Inc. Multiple fluid dispensing device for low surface tension formulations
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2237898A1 (en) 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
WO1999051273A1 (en) * 1998-04-07 1999-10-14 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6146622A (en) 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI292914B (enExample) * 2002-01-17 2008-01-21 Macronix Int Co Ltd
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
KR100521364B1 (ko) * 2002-11-18 2005-10-12 삼성전자주식회사 플레쉬 메모리 셀들의 프로그램 오판을 방지하고 균일한문턱 전압 산포를 가질 수 있는 플레쉬 메모리 장치 및 그프로그램 검증 방법

Also Published As

Publication number Publication date
US20160303119A1 (en) 2016-10-20
ES2399045T3 (es) 2013-03-25
US8133890B2 (en) 2012-03-13
AU2003228480B2 (en) 2006-07-27
US20130324534A1 (en) 2013-12-05
US20180042932A1 (en) 2018-02-15
US20170157138A1 (en) 2017-06-08
US9907802B1 (en) 2018-03-06
US9770453B2 (en) 2017-09-26
CN1516588A (zh) 2004-07-28
US20080132512A1 (en) 2008-06-05
KR100723189B1 (ko) 2007-05-29
WO2003088973A1 (en) 2003-10-30
US20120184551A1 (en) 2012-07-19
CN101664414A (zh) 2010-03-10
BR0302584A (pt) 2004-03-09
US20030199509A1 (en) 2003-10-23
US8354409B2 (en) 2013-01-15
US20210405280A1 (en) 2021-12-30
TWI351959B (en) 2011-11-11
EP1496912A1 (en) 2005-01-19
TW200402296A (en) 2004-02-16
CN100558364C (zh) 2009-11-11
US20150087647A1 (en) 2015-03-26
US7030149B2 (en) 2006-04-18
HK1067549A1 (zh) 2005-06-03
NO326579B1 (no) 2009-01-12
EP2241319A1 (en) 2010-10-20
US7320976B2 (en) 2008-01-22
CY1114048T1 (el) 2016-07-27
DK1496912T3 (da) 2013-04-02
US9907801B1 (en) 2018-03-06
US7323463B2 (en) 2008-01-29
US20130116255A1 (en) 2013-05-09
US8748425B2 (en) 2014-06-10
MX368377B (es) 2019-09-30
NO20044450L (no) 2004-11-09
MXPA03008401A (es) 2004-03-16
AU2003228480A1 (en) 2003-11-03
US9474751B1 (en) 2016-10-25
CA2440764A1 (en) 2003-10-19
US20180064721A1 (en) 2018-03-08
US20180064720A1 (en) 2018-03-08
US20040102445A1 (en) 2004-05-27
PT1496912E (pt) 2013-02-13
KR20040100844A (ko) 2004-12-02
EP1496912B1 (en) 2013-01-09
JP2005523316A (ja) 2005-08-04
EP1496912B9 (en) 2015-06-17
US20030199507A1 (en) 2003-10-23
US20130196995A1 (en) 2013-08-01
NZ528945A (en) 2006-04-28
US20200129520A1 (en) 2020-04-30
CA2440764C (en) 2005-10-25

Similar Documents

Publication Publication Date Title
PT1496912E (pt) Combinação de brimonidina e timolol para utilização oftálmica tópica
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2003263345A1 (en) Sulphonamide derivatives and their use as tace inhibitors
PL376715A1 (pl) Kompozycja terapeutyczna do skóry do stosowania miejscowego
AU2003265225A1 (en) Preparations for topical skin use and treatment
IL164211A0 (en) Il-18 inhibitors and peripheral vascular diseases
AU2003299064A1 (en) Packaged personal care compositions
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
AU2002951082A0 (en) Therapeutic cellular agents
AU2003255413A1 (en) Use of lck inhibitor for treatment of immunologic diseases
AU2002353777A1 (en) Saliva-based methods for preventing and assessing the risk of diseases
EG24403A (en) Ophthalmic composition
GB0207411D0 (en) Azole compounds and their therapeutic use
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU2003242755A1 (en) Novel pharmaceutical compositions comprising novel anticholinergic agents and pde-iv inhibitors
AU2003275304A1 (en) Use of caspase inhibitors as therapeutic agent against radiation-induced injury
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2003201853A1 (en) Skin preparations for external use
AU2003250999A1 (en) Cosmetic use of lignans
AU2003240446A1 (en) Use of mob-5 in pain
AU2003232217A1 (en) Use of agmatine for topical application
AU2003296060A1 (en) Ophthalmic therapeutic composition
AU2002101009A4 (en) Personal body treatment